Recently, Rosenberg's group used TCR gene therapy derived from a Treg clonotype to drive the response to the germline antigen MAGE-A3, and demonstrated its safety and efficacy in metastatic cancers of different origins (14). The gene discussed is MAGEA3; the disease is metastatic malignant neoplasm.